Cargando…

Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts

Prostate specific membrane antigen (PSMA) represents a validated target for prostate cancer therapeutics. The phase III VISION study with (177)lutetium ((177)Lu)-PSMA-617 represented a pivotal step forward and the FDA has now approved this agent in advanced metastatic castrate-resistant prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sartor, Oliver, Baghian, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763319/ https://www.ncbi.nlm.nih.gov/pubmed/36561718 http://dx.doi.org/10.3389/fmed.2022.1060922

Ejemplares similares

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023)

Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer
por: Shen, Colette J., et al.
Publicado: (2020)

Small Molecule Radiopharmaceuticals – A Review of Current Approaches
por: Chaturvedi, Shubhra, et al.
Publicado: (2016)

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives
por: Lepareur, Nicolas, et al.
Publicado: (2019)

Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology
por: Barbet, Jacques, et al.
Publicado: (2017)

Editorial: Reviews in: Radiopharmaceuticals in nuclear medicine
por: Lau, Chuen-Yen, et al.
Publicado: (2023)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Cold Kit Labeling: The Future of (68)Ga Radiopharmaceuticals?
por: Lepareur, Nicolas
Publicado: (2022)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
por: Ben Jemaa , Awatef, et al.
Publicado: (2010)

Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium‐177 prostate‐specific membrane antigen (PSMA) therapy
por: Zoberi, Jacqueline E., et al.
Publicado: (2023)

Highlights of the Latest Developments in Radiopharmaceuticals for Infection Imaging and Future Perspectives
por: Dadachova, Ekaterina, et al.
Publicado: (2022)

Prostate-Specific Antigen Velocity Predicts Surgical Outcome of Thulium Laser Enucleation of the Prostate
por: Chen, Po-You, et al.
Publicado: (2022)

Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
por: Pallares, Roger M., et al.
Publicado: (2022)

18F-Prostate-Specific Membrane Antigen and 18F-Fluorodeoxyglucose PET/CT Unmasked the Characteristics of Prostate Lymphoma: A Case Report and Literature Review
por: Jiang, Fan, et al.
Publicado: (2022)

Optimized Application of (68)Ga-Prostate-Specific Membrane Antigen-617 Whole-Body PET/CT and Pelvic PET/MR in Prostate Cancer Initial Diagnosis and Staging
por: Qin, Chunxia, et al.
Publicado: (2021)

The Scientific and Clinical Case for Reviewing Diagnostic Radiopharmaceutical Extravasation Long-Standing Assumptions
por: Osborne, Dustin, et al.
Publicado: (2021)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

Current status and future perspective of radiopharmaceuticals in China
por: Hu, Ji, et al.
Publicado: (2021)

PET Oncological Radiopharmaceuticals: Current Status and Perspectives
por: Lin, Mai, et al.
Publicado: (2022)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?
por: Céspedes, Melissa Segura, et al.
Publicado: (2021)

New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer
por: Li, Xin, et al.
Publicado: (2020)

Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
por: Inubushi, Masayuki, et al.
Publicado: (2020)

Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting (68)Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer
por: Suh, Minseok, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen-Based Therapeutics
por: Akhtar, Naveed H., et al.
Publicado: (2012)

Biomarkers in Prostate-Specific Membrane Antigen Theranostics
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Updates of prostate cancer staging: Prostate-specific membrane antigen
por: Sathianathen, Niranjan J, et al.
Publicado: (2016)

Prostate-specific membrane antigen-mediated theragnostics in prostate cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2021)

Incidental prostate-specific membrane antigen-avid meningioma detected on (68)Ga–prostate-specific membrane antigen PET/CT
por: Jiang, James Yuheng, et al.
Publicado: (2021)

Incidental prostate-specific membrane antigen-avid glioblastoma detected on (68)Ga–prostate-specific membrane antigen PET/CT
por: Jiang, James Yuheng, et al.
Publicado: (2022)

Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
por: Chen, Jiaxian, et al.
Publicado: (2022)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane
por: Godeiro, Katyanne Dantas, et al.
Publicado: (2006)

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
por: Cimadamore, Alessia, et al.
Publicado: (2018)

Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors
por: Jung, Ji-hoon, et al.
Publicado: (2018)

(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study)
por: Rahbar, Kambiz, et al.
Publicado: (2023)

Radiopharmaceuticals for therapy
por: Knapp, F F (Russ), et al.
Publicado: (2016)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

Pharmacovigilance in radiopharmaceuticals
por: Kumar, Rishi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0jebmd0rn712td131hh35ra9de